	US 12,227,595 B2
	Anti-renalase antibodies for the treatment and prevention of diseases and disorders
Gary Desir, Woodbridge, CT (US); and Bryce Nelson, West Haven, CT (US)
Assigned to Yale University, New Haven, CT (US)
Appl. No. 16/958,960
Filed by Yale University, New Haven, CT (US)
PCT Filed Dec. 27, 2018, PCT No. PCT/US2018/067611 § 371(c)(1), (2) Date Jun. 29, 2020, PCT Pub. No. WO2019/133667, PCT Pub. Date Jul. 4, 2019.
Claims priority of provisional application 62/611,609, filed on Dec. 29, 2017.
Prior Publication US 2022/0348684 A1, Nov. 3, 2022
Int. Cl. C07K 16/40 (2006.01); G01N 33/574 (2006.01)

CPC C07K 16/40 (2013.01) [G01N 33/5743 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01)]

11 Claims

1. A composition comprising an antibody or binding portion thereof that specifically binds to renalase, wherein the antibody or binding portion thereof comprises: a) a heavy chain (HC) CDR1 comprising the amino acid sequence of SEQ ID NO: 191, b) a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 192, c) a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 193, d) a light chain (LC) CDR1 comprising the amino acid sequence of SEQ ID NO: 188, e) a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 189, and f) a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 190.